NO924209L - Doseringsform for tilfoersel av et antiparkinsonmiddel - Google Patents

Doseringsform for tilfoersel av et antiparkinsonmiddel

Info

Publication number
NO924209L
NO924209L NO92924209A NO924209A NO924209L NO 924209 L NO924209 L NO 924209L NO 92924209 A NO92924209 A NO 92924209A NO 924209 A NO924209 A NO 924209A NO 924209 L NO924209 L NO 924209L
Authority
NO
Norway
Prior art keywords
dosage form
administration
parkinson agent
parkinson
agent
Prior art date
Application number
NO92924209A
Other languages
English (en)
Norwegian (no)
Other versions
NO924209D0 (no
Inventor
David Emil Edgren
Howard A Carpenter
Gurdish Kaur Bhatti
Atul Devdatt Ayer
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO924209D0 publication Critical patent/NO924209D0/no
Publication of NO924209L publication Critical patent/NO924209L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
NO92924209A 1990-05-07 1992-11-02 Doseringsform for tilfoersel av et antiparkinsonmiddel NO924209L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/520,295 US5190763A (en) 1990-05-07 1990-05-07 Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
PCT/US1991/002995 WO1991016885A1 (en) 1990-05-07 1991-05-01 Dosage form to deliver an antiparkinson agent

Publications (2)

Publication Number Publication Date
NO924209D0 NO924209D0 (no) 1992-11-02
NO924209L true NO924209L (no) 1992-11-09

Family

ID=24071988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924209A NO924209L (no) 1990-05-07 1992-11-02 Doseringsform for tilfoersel av et antiparkinsonmiddel

Country Status (17)

Country Link
US (1) US5190763A (da)
EP (1) EP0527835B1 (da)
JP (1) JP2634322B2 (da)
KR (1) KR0169146B1 (da)
AT (1) ATE113203T1 (da)
AU (1) AU641770B2 (da)
CA (1) CA2041579C (da)
DE (1) DE69104830T2 (da)
DK (1) DK0527835T3 (da)
ES (1) ES2067231T3 (da)
FI (1) FI925029A (da)
IE (1) IE62397B1 (da)
NO (1) NO924209L (da)
NZ (2) NZ238011A (da)
PT (1) PT97552B (da)
WO (1) WO1991016885A1 (da)
ZA (1) ZA913282B (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JPH11506744A (ja) * 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
DE69902520T2 (de) 1998-03-16 2003-04-10 Somerset Pharmaceuticals Inc Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE19855704C2 (de) 1998-12-03 2002-08-01 Lothar Saiger Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
AP2002002553A0 (en) * 1999-12-23 2002-06-30 Pfizer Prod Inc Hydrogel-driven Drug Dosoge Form.
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
EP1441708B1 (en) * 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
BR0309113A (pt) * 2002-04-11 2005-02-01 Ranbaxy Lab Ltd Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas
EP1622450A4 (en) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
JP2005309912A (ja) * 2004-04-23 2005-11-04 Oki Data Corp 画像形成装置
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
PT2982372T (pt) 2005-04-05 2020-10-09 Univ Yale Agentes moduladores do glutamato no tratamento de distúrbios mentais
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
RU2429223C2 (ru) * 2005-12-05 2011-09-20 Ксенопорт, Инк. Мезилатное пролекарство леводопы, его композиции и применение
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CL2007002574A1 (es) * 2006-09-08 2008-05-23 Drug Tech Corp Sa Organizada B Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson.
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
JP2011502953A (ja) * 2006-12-21 2011-01-27 ゼノポート，インコーポレーテッド ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
RU2540470C9 (ru) † 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
JP6199539B2 (ja) * 2009-03-12 2017-09-20 デルポー，インコーポレイティド 薬物の長期送達のための埋め込み型装置
AU2010315892B2 (en) 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP3672581A4 (en) 2017-08-24 2021-05-19 Adamas Pharma, LLC AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing

Also Published As

Publication number Publication date
DE69104830D1 (de) 1994-12-01
NO924209D0 (no) 1992-11-02
US5190763A (en) 1993-03-02
ATE113203T1 (de) 1994-11-15
PT97552B (pt) 1998-08-31
NZ238011A (en) 1995-12-21
DK0527835T3 (da) 1995-04-18
FI925029A0 (fi) 1992-11-06
NZ248491A (en) 1995-12-21
KR0169146B1 (ko) 1999-01-15
FI925029A (fi) 1992-11-06
AU7854391A (en) 1991-11-27
ZA913282B (en) 1992-02-26
DE69104830T2 (de) 1995-03-02
WO1991016885A1 (en) 1991-11-14
EP0527835A1 (en) 1993-02-24
PT97552A (pt) 1992-01-31
JPH05506858A (ja) 1993-10-07
AU641770B2 (en) 1993-09-30
JP2634322B2 (ja) 1997-07-23
KR930700076A (ko) 1993-03-13
EP0527835B1 (en) 1994-10-26
ES2067231T3 (es) 1995-03-16
IE911466A1 (en) 1991-11-20
CA2041579A1 (en) 1991-11-08
IE62397B1 (en) 1995-01-25
CA2041579C (en) 2003-09-30

Similar Documents

Publication Publication Date Title
NO924209L (no) Doseringsform for tilfoersel av et antiparkinsonmiddel
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
NO306377B1 (no) Doseform for avgivelse av et medikament
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ES2060941T3 (es) Uso de nicotina para la fabricacion de un estuche para el tratamiento de condiciones susceptibles de dicho tratamiento.
NO171145C (no) Fremgangsmaate for fremstilling av en fettemulsjon med et hydrofobt medikament
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
SE9101341D0 (sv) New medicinal use
ES2077032T3 (es) Mejoras en el tratamiento de la esterilidad.
RU94020964A (ru) Электростатический пластырь "элпласт"
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
SE8903117D0 (sv) Laekemedel omfattande antamanid
RU95101640A (ru) Лекарственное средство для лечения дислипопротеидемии
KR910015299A (ko) 우울증 치료방법
RU93043494A (ru) Способ и приспособление для воздействия ультрамалыми дозами лекарственных средств